Multidisciplinary Approach to Care
The Lymphoma Research Consortium combines excellent patient care with research and is dedicated to finding a cure for the both Hodgkin and non-Hodgkin lymphomas.
Established a comprehensive multidisciplinary clinical treatment team with expertise in combined modality treatments, high-dose treatments with bone marrow/stem cell transplant, monoclonal antibody treatment (including radioimmunotherapy), and investigational new therapies for recurrent/resistant disease.
Lymphoma Medical Oncology
The Medical Oncology section of the Lymphoma Research Consortium offers:
- Combined modality treatments, high-dose treatments with bone marrow/stem cell transplants and monoclonal antibody treatment
- Investigational new therapies for recurrent/resistant disease
- Clinical trials that bring the most active new agents to our patients.
- Laboratory research on lymphoma biology
- The exploration of new strategies to prevent, diagnose and cure lymphomas
Lymphoma Research Consortium accomplishments over the last three decades:
- The University of Arizona Cancer Center, along with the James P. Wilmot Cancer Center at the University of Rochester, obtained one of five Specialized Research Consortiums of Research Excellence (SPORE) grants in Lymphoma, funded by the National Cancer Institute.
- Developed state-of-the-art diagnostic capabilities benefiting patients referred to the Cancer Center or treated throughout Arizona.
- Identified optimal treatment for localized (limited) non-Hodgkin lymphoma.
- Established the benchmark for treatment of advanced aggressive non-Hodgkin lymphoma
- Designed and participated in studies showing a 70% reduction in death for patients with follicular non-Hodgkin lymphoma.
- Made seminal contributions to the Lymphoma/Leukemia Molecular Profiling Project.
- Gained insight as to why treatment fails (tumor cell characteristics, drug resistance).
- Demonstrated that drug resistance can be reversed.
- Developed automated systems for laboratory evaluation of lymphomas.
- Investigations of new ways to detect and monitor cancer (biomarkers).
Current areas of research are focused on:
- Determining the relationship of specific tumor gene expression patterns to treatment outcome.
- Understanding the contribution of the intracellular redox environment to lymphoma biology and treatment response.
- Understanding how the tumor microenvironment and host response affect patient survival.
- Identifying new therapies targeted to take advantage of unique tumor characteristics.
- Developing new technologies for translational research, in collaboration with Ventana Medical Systems, Inc.
- The University of Arizona Cancer Center’s Lymphoma Research Consortium includes National Cancer Institute, American Cancer Society and philanthropy funding for the Lymphoma Consortium, Arizona Lymphoma Tumor Bio-Repository, Lymphoma Translational Medicine Committee, as well as research on lymphoma gene expression signatures and support for translational research objectives of specific clinical trials.
Lymphoma Research Consortium Members:
Ryan Avery, MD, Nuclear Medicine
Amanda Baker, PharmD PhD, Lymphoma research
Margaret Briehl, PhD, Lymphoma research
Clara Curiel, MD, Dermatologic Oncology
Deborah Fuchs, MD, Hematopathology
Victor Gonzalez, MD, Radiation Oncology
Marlon Guerrero, MD, Surgical Oncology
Laurence Hurley, PhD, Lymphoma Research
Sam Kim, MD, Surgical Oncology
Philip Kuo, MD PhD, Nuclear Medicine
Daruka Mahadevan, MD PhD, Medical Oncology/Phase I trials
Daniel Persky, MD, Medical Oncology
Maria Proytcheva, MD, Hematopathology
Monika Schmelz, PhD, Lymphoma research
Catharine Smith, PhD, Lymphoma research
Catherine Spier, MD, Hematopathology
Baldassarre “Dino” Stea, MD PhD, Radiation Oncology
James Warneke, MD, Surgical Oncology
Emily Crawford, BS, Lymphoma team Coordinator
Lora Inclan, BA, Clinical Trials Coordination